ArticleJournal of virology2015
Biological and protective properties of immune sera directed to the influenza virus neuraminidase.
Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.Vaccine · 2025Trial
- Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies.Veterinary and animal science · 2026Review
- Non-propagating RNA virus-vectored HA/NA vaccine prevents shedding of antigen-drifted H1N1 influenza virus in pigs.NPJ vaccines · 2026Article
- Avian influenza and One Health: bridging animal and human health through integrated surveillance and vaccination.Frontiers in cellular and infection microbiology · 2026Review
- Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model.PLoS pathogens · 2024Article
- Reassortment incompetent live attenuated and replicon influenza vaccines provide improved protection against influenza in piglets.NPJ vaccines · 2024Article
- Sequential vaccinations with divergent H1N1 influenza virus strains induce multi-H1 clade neutralizing antibodies in swine.Nature communications · 2023Article
- Article
- The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.Vaccines · 2021Review
- Article
- Article
- Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.Journal of virology · 2019Article
- Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.Virology · 2019Article
- The role of cell surface expression of influenza virus neuraminidase in induction of human lymphocyte apoptosis.Virology · 2019Article
- Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs.mBio · 2019Article
- Regional patterns of genetic diversity in swine influenza A viruses in the United States from 2010 to 2016.Influenza and other respiratory viruses · 2019Article
- Heterotypic Neuraminidase Antibodies Against Different A(H1N1) Strains are Elicited after Seasonal Influenza Vaccination.Vaccines · 2019Article
- What can we learn about influenza infection and vaccination from transcriptomics?Human vaccines & immunotherapeutics · 2019Review
- Article
- Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.Journal of virology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe envelope of influenza A viruses contains two large antigens, hemagglutinin (HA) and neuraminidase (NA). Conventional influenza virus vaccines induce neutralizing antibodies that are predominantly directed to the HA globular head, a domain that is subject to extensive antigenic drift. Antibodies directed to NA are induced at much lower levels, probably as a consequence of the immunodominance of the HA antigen. Although antibodies to NA may affect virus release by inhibiting the sialidase function of the glycoprotein, the antigen has been largely neglected in past vaccine design. In this study, we characterized the protective properties of monospecific immune sera that were generated by vaccination with recombinant RNA replicon particles encoding NA. These immune sera inhibited hemagglutination in an NA subtype-specific and HA subtype-independent manner and interfered with infection of MDCK cells. In addition, they inhibited the sialidase activities of various influenza viruses of the same and even different NA subtypes. With this, the anti-NA immune sera inhibited the spread of H5N1 highly pathogenic avian influenza virus and HA/NA-pseudotyped viruses in MDCK cells in a concentration-dependent manner. When chickens were immunized with NA recombinant replicon particles and subsequently infected with low-pathogenic avian influenza virus, inflammatory serum markers were significantly reduced and virus shedding was limited or eliminated. These findings suggest that NA antibodies can inhibit virus dissemination by interfering with both virus attachment and egress. Our results underline the potential of high-quality NA antibodies for controlling influenza virus replication and place emphasis on NA as a vaccine antigen. IMPORTANCE: The neuraminidase of influenza A viruses is a sialidase that acts as a receptor-destroying enzyme facilitating the release of progeny virus from infected cells. Here, we demonstrate that monospecific anti-NA immune sera inhibited not only sialidase activity, but also influenza virus hemagglutination and infection of MDCK cells, suggesting that NA antibodies can interfere with virus attachment. Inhibition of both processes, virus release and virus binding, may explain why NA antibodies efficiently blocked virus dissemination in vitro and in vivo. Anti-NA immune sera showed broader reactivity than anti-HA sera in hemagglutination inhibition tests and demonstrated cross-subtype activity in sialidase inhibition tests. These remarkable features of NA antibodies highlight the importance of the NA antigen for the development of next-generation influenza virus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.